Download presentation
Presentation is loading. Please wait.
Published byGonzalo Padilla Páez Modified over 6 years ago
1
What Anticoagulant Registries Are Revealing
3
Clinical Trials vs Registries
4
AFNET Registry: Cardiologist-run Centers Adhere Better to Antithrombotic Guidelines
5
VKA vs Dabigatran in "Real Life" (US Medicare)
6
Clinical Trials vs Registries
7
GLORIA-AF
8
GARFIELD
9
Antithrombotic Therapy in AF 2004-06 EUROHEART[a] and AFNET[b] Registry Analyses
10
Antithrombotic Therapy by Stroke Risk Score
11
Anticoagulant Use By CHA2DS2-VASc Score
12
GLORIA-AF Increasing Uptake of NOACs vs VKAs in Most Regions
13
GLORIA-AF: Increasing NOAC Uptake in Europe- Phase I versus Phase II
14
Real-World Studies EORP – AF pilot
15
NOAC Meta-analysis Stroke or SEE
16
Why Don't Elderly Patients Receive NOACs/VKAs?
17
Anticoagulant + Antiplatelet Therapy in Patients With AF at Risk for Stroke
18
PREFER-AF Combination Therapy (OAC and Antiplatelets) in Europe in 2012
19
Dabigatran and Cardioversion
20
New NOAC Cardioversion Trials
21
Summary
22
Abbreviations
23
References
24
References (cont)
25
References (cont)
26
References (cont)
27
References (cont)
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.